title: [Treatment of cutaneous T-cell lymphoma with retinoid receptor X-selective ligands: endocrine and metabolic disorders].
abstract: The retinoid X receptor-selective ligands has been used for advanced stages of cutaneous T-cell lymphoma refractory to previous systemic therapy, being bexarotene the first drug in this group approved in Europe. Multiple drug-related adverse events has been reported such as endocrine-metabolic disorders. We report 2 patients with cutaneous T-cell lymphoma, treated with bexarotene, that developed central hypothyroidism and dislipidaemia inmediately after the begining of this treatment. We also showed the successfully treatment response of these alterations and the total clinical remission after discontinuing the drug.
authors.affiliation: Servicios de Endocrinología, Complejo Hospitalario Universitario, Badajoz, Spain.
authors.forename: M D
authors.initials: MD
authors.lastname: Avilés Pérez
authors.forename: V
authors.initials: V
authors.lastname: Luna López
authors.forename: I
authors.initials: I
authors.lastname: Rodríguez Nevado
authors.forename: D
authors.initials: D
authors.lastname: de Argila Fernández-Durán
authors.forename: J
authors.initials: J
authors.lastname: Díaz Pérez de Madrid
mesh_terms: D016588:Anticarcinogenic Agents / Q000009:adverse effects*; D000077610:Bexarotene; D050171:Dyslipidemias / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced*; D008024:Ligands; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D047488:Retinoid X Receptors; D012878:Skin Neoplasms / Q000188:drug therapy*; D013764:Tetrahydronaphthalenes / Q000009:adverse effects*
chemical_list: D016588:Anticarcinogenic Agents; D008024:Ligands; D047488:Retinoid X Receptors; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene